Alps Advisors Inc Cardiff Oncology, Inc. Transaction History

Alps Advisors Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.17 - $2.61 $52,077 - $116,173	-44,511 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $8,541 - $29,348	-4,048 Reduced 8.34%	44,511 $110,000
Q4 2021 Feb 09, 2022	BUY	$5.18 - $7.24 $445 - $622	86 Added 0.18%	48,559 $292,000
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $4,939 - $7,473	-986 Reduced 1.99%	48,473 $323,000
Q2 2021 Aug 11, 2021	BUY	$6.65 - $10.04 $328,902 - $496,568	49,459 New	49,459 $329,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $170M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.